Tesaro, Inc. (TSRO) Analysts See $-2.77 EPS

April 22, 2018 - By Ellis Scott

Tesaro, Inc. (NASDAQ:TSRO) LogoInvestors sentiment decreased to 1.01 in Q4 2017. Its down 0.20, from 1.21 in 2017Q3. It turned negative, as 46 investors sold Tesaro, Inc. shares while 64 reduced holdings. 39 funds opened positions while 72 raised stakes. 57.95 million shares or 0.57% less from 58.28 million shares in 2017Q3 were reported.
Greenwood Capital Lc holds 2,681 shares or 0.05% of its portfolio. Strs Ohio stated it has 0% in Tesaro, Inc. (NASDAQ:TSRO). Gulf Savings Bank (Uk) Limited holds 11,780 shares or 0.01% of its portfolio. Citigroup Incorporated invested in 207,737 shares. Camber Mngmt Limited Liability, Massachusetts-based fund reported 850,000 shares. Arrowmark Colorado Ltd Llc, Colorado-based fund reported 17,627 shares. Moreover, Ivory Inv Management Ltd Limited Liability Company has 0.67% invested in Tesaro, Inc. (NASDAQ:TSRO). Old Mutual Customised Solutions (Proprietary) accumulated 0.01% or 1,500 shares. Huntington National Bank invested 0% in Tesaro, Inc. (NASDAQ:TSRO). California State Teachers Retirement System owns 60,609 shares for 0.01% of their portfolio. 278,789 were reported by Tiaa Cref Inv Mgmt Limited Liability. Ftb Incorporated reported 84 shares or 0% of all its holdings. Nomura Asset has 4,000 shares. Fjarde Ap stated it has 0.02% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Dimensional Fund Advsr Limited Partnership has invested 0% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO).

Since March 1, 2018, it had 9 insider purchases, and 7 insider sales for $61.19 million activity. NEW ENTERPRISE ASSOCIATES 13 LP had bought 116,445 shares worth $6.68M on Friday, March 2. Oliveira Orlando had sold 3,000 shares worth $209,640. The insider Viswanathan Ravi bought $8.35M. 145,532 shares were bought by MOTT DAVID M, worth $8.35 million on Friday, March 2. The insider BARRIS PETER J bought 145,532 shares worth $8.35 million. Another trade for 5,000 shares valued at $284,640 was bought by MOULDER LEON O JR.

Analysts expect Tesaro, Inc. (NASDAQ:TSRO) to report $-2.77 EPS on May, 8.They anticipate $0.22 EPS change or 8.63 % from last quarter’s $-2.55 EPS. After having $-3.35 EPS previously, Tesaro, Inc.’s analysts see -17.31 % EPS growth. The stock decreased 1.21% or $0.63 during the last trading session, reaching $51.58. About 609,519 shares traded. Tesaro, Inc. (NASDAQ:TSRO) has declined 63.82% since April 22, 2017 and is downtrending. It has underperformed by 75.37% the S&P500.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Among 12 analysts covering Tesaro (NASDAQ:TSRO), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Tesaro has $165 highest and $65.0 lowest target. $112.83’s average target is 118.75% above currents $51.58 stock price. Tesaro had 17 analyst reports since October 23, 2017 according to SRatingsIntel. As per Wednesday, February 28, the company rating was maintained by Cowen & Co. Leerink Swann maintained Tesaro, Inc. (NASDAQ:TSRO) on Wednesday, February 28 with “Buy” rating. Morgan Stanley maintained it with “Overweight” rating and $146 target in Thursday, March 1 report. The firm has “Hold” rating given on Thursday, January 18 by Piper Jaffray. Piper Jaffray downgraded Tesaro, Inc. (NASDAQ:TSRO) rating on Monday, October 23. Piper Jaffray has “Hold” rating and $117.0 target. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, November 8. The stock of Tesaro, Inc. (NASDAQ:TSRO) earned “Buy” rating by Guggenheim on Wednesday, January 3. The firm has “Outperform” rating given on Thursday, February 22 by Evercore. The rating was maintained by Piper Jaffray on Monday, April 16 with “Hold”. Credit Suisse maintained it with “Outperform” rating and $141 target in Wednesday, February 28 report.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $2.83 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.